GSK Bio
NEWS
Former Principal at Wellington Partners Life Sciences appointed to drive Fund’s European investments
After Joichi “Joi” Ito resigned from his post as director of the MIT Media Lab following revelations of his connections with disgraced financier Jeffrey Epstein, Boston-based Puretech Health announced this morning that he has also resigned from his position as chairman of that company’s board of directors.
Crescendo Biologics Ltd announces that Stewart Kay has been appointed as the Company’s Chief Business Officer.
In addition, Sumitomo Dainippon is acquiring an equity stake of more than 10% of Roivant shares.
Orchard Therapeutics announced data from an ongoing proof-of-concept clinical trial evaluating the safety and efficacy of OTL-203, a gene therapy for the treatment of mucopolysaccharidosis type I developed at the San Raffaele-Telethon Institute for Gene Therapy in Milan.
Orchard Therapeutics announced results from an integrated data analysis of OTL-200, a gene therapy in development for the treatment of metachromatic leukodystrophy (MLD) at the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy.
World-renowned drug discovery experts to advance C4XD capabilities
The TULIP 2 trial was the second Phase III trial that assessed the safety and efficacy of anifrolumab as a treatment for adults with moderate-to-severe SLE.
On Tuesday, the U.K. pharma giant optioned to license an antisense treatment from Ionis Pharmaceuticals following positive Phase II results in chronic hepatitis B virus infection.
JOBS
IN THE PRESS